ASX:ATXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Amplia Therapeutics Ltd
$0.150
Day Range
$0.145 – $0.155
52 Week Range
$0.100 – $0.275
Volume
964.97K
Avg Volume (10D)
2.32M
Market Cap
$77.00M
Price Chart
Market Statistics
Open$0.150
Previous Close$0.150
Day High$0.155
Day Low$0.145
52 Week High$0.275
52 Week Low$0.100
Valuation
Market Cap77.00M
Shares Outstanding513.31M
Price to Book1.95
Trading Activity
Volume964.97K
Value Traded143.89K
Bid$0.150 × 88,630
Ask$0.155 × 96,897
Performance
1 Day-3.23%
5 Day20.00%
13 Week11.11%
52 Week-14.29%
YTD0.00%
Technical Indicators
RSI (14)58.08
50-Day SMA$0.133
200-Day SMA$0.139
Latest News
Biotechnology
Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial
Amplia Therapeutics partners with Eli Lilly for a Phase 1b/2b NSCLC trial of narmafotinib plus olomorasib, targeting KRAS G12C resistance and expanding market.
Biotechnology
Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG
Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.
Biotechnology
Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs
Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.
Biotechnology
Amplia Therapeutics Reports Stronger Efficacy and Survival in Pancreatic Cancer Trial
Amplia Therapeutics reports ACCENT trial: 7.8% CR, 35.9% ORR, 11.1-month median OS in pancreatic cancer; trading halt ahead of AACR.